{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T13:30:53Z","timestamp":1782307853055,"version":"3.54.5"},"reference-count":58,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.leukres.2023.107341","type":"journal-article","created":{"date-parts":[[2023,6,15]],"date-time":"2023-06-15T11:34:16Z","timestamp":1686828856000},"page":"107341","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Should patients with acute myeloid leukemia treated with venetoclax-based regimens receive antifungal prophylaxis?"],"prefix":"10.1016","volume":"131","author":[{"given":"Mariana","family":"Guarana","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4867-0014","authenticated-orcid":false,"given":"Marcio","family":"Nucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.leukres.2023.107341_bib1","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1097\/QCO.0b013e328358b000","article-title":"Risks for infection in patients with myelodysplasia and acute leukemia","volume":"25","author":"Pagano","year":"2012","journal-title":"Curr. Opin. Infect. Dis."},{"issue":"1","key":"10.1016\/j.leukres.2023.107341_bib2","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s12879-023-08013-5","article-title":"Effect of invasive aspergillosis on risk for different causes of death in older patients with acute myeloid leukaemia or high-risk myelodysplastic syndrome","volume":"23","author":"van Grootveld","year":"2023","journal-title":"BMC Infect. Dis."},{"issue":"2","key":"10.1016\/j.leukres.2023.107341_bib3","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/BF01967060","article-title":"Fungal infections in cancer patients: an international autopsy survey","volume":"11","author":"Bodey","year":"1992","journal-title":"Eur. J. Clin. Microbiol Infect. Dis."},{"issue":"2","key":"10.1016\/j.leukres.2023.107341_bib4","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.diagmicrobio.2012.10.001","article-title":"Epidemiology, outcomes, and risk factors of invasive fungal infections in adult patients with acute myelogenous leukemia after induction chemotherapy","volume":"75","author":"Neofytos","year":"2013","journal-title":"Diagn. Microbiol. Infect. Dis."},{"issue":"8","key":"10.1016\/j.leukres.2023.107341_bib5","first-page":"1068","article-title":"The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study","volume":"91","author":"Pagano","year":"2006","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.leukres.2023.107341_bib6","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1056\/NEJMoa061094","article-title":"Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia","volume":"356","author":"Cornely","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2023.107341_bib7","doi-asserted-by":"crossref","unstructured":"J.A. Maertens, C. Girmenia, R.J. Bruggemann, R.F. Duarte, C.C. Kibbler, P. Ljungman, Z. Racil, P. Ribaud, M.A. Slavin, O.A. Cornely, J. Peter Donnelly, C. Cordonnier, a.j.v.o.t.E.G.f.B. European Conference on Infections in Leukaemia, t.E.O.f.R. Marrow Transplantation, t.I.H.S.a. Treatment of Cancer, a.j.v.o.t.E.G.f.B. European Conference on Infections in Leukaemia, t.E.O.f.R. Marrow Transplantation, t.I.H.S. Treatment of Cancer, L. the European, European guidelines for primary antifungal prophylaxis in adult haematology patients: summary of the updated recommendations from the European Conference on Infections in Leukaemia, J Antimicrob Chemother 73(12) (2018) 3221\u20133230.","DOI":"10.1093\/jac\/dky286"},{"issue":"2","key":"10.1016\/j.leukres.2023.107341_bib8","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s00277-017-3196-2","article-title":"Primary prophylaxis of invasive fungal infections in patients with haematological malignancies: 2017 update of the recommendations of the infectious diseases working party (AGIHO) of the German society for haematology and medical oncology (DGHO)","volume":"97","author":"Mellinghoff","year":"2018","journal-title":"Ann. Hematol."},{"issue":"Suppl 7","key":"10.1016\/j.leukres.2023.107341_bib9","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/imj.15588","article-title":"Antifungal guidelines steering, consensus guidelines for antifungal prophylaxis in haematological malignancy and haemopoietic stem cell transplantation, 2021","volume":"51","author":"Teh","year":"2021","journal-title":"Intern. Med. J."},{"issue":"11","key":"10.1016\/j.leukres.2023.107341_bib10","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1093\/cid\/cis773","article-title":"Evaluation of the practice of antifungal prophylaxis use in patients with newly diagnosed acute myeloid leukemia: results from the SEIFEM 2010-B registry","volume":"55","author":"Pagano","year":"2012","journal-title":"Clin. Infect. Dis."},{"issue":"3","key":"10.1016\/j.leukres.2023.107341_bib11","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1111\/myc.13205","article-title":"Epidemiology of invasive fungal disease in haematologic patients","volume":"64","author":"Souza","year":"2021","journal-title":"Mycoses"},{"issue":"7","key":"10.1016\/j.leukres.2023.107341_bib12","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.leukres.2023.107341_bib13","first-page":"1609","article-title":"Multicenter registry of patients receiving systemic mold-active triazoles for the management of invasive fungal infections","volume":"11","author":"Ostrosky-Zeichner","year":"2022","journal-title":"Infect. Dis. Ther."},{"issue":"9","key":"10.1016\/j.leukres.2023.107341_bib14","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1093\/cid\/ciac230","article-title":"Comparison of mold active triazoles as primary antifungal prophylaxis in patients with newly diagnosed acute myeloid leukemia in the era of molecularly targeted therapies","volume":"75","author":"Rausch","year":"2022","journal-title":"Clin. Infect. Dis."},{"issue":"6","key":"10.1016\/j.leukres.2023.107341_bib15","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1097\/QCO.0000000000000611","article-title":"Azole antifungals and new targeted therapies for hematological malignancy","volume":"32","author":"Lindsay","year":"2019","journal-title":"Curr. Opin. Infect. Dis."},{"issue":"26","key":"10.1016\/j.leukres.2023.107341_bib16","doi-asserted-by":"crossref","first-page":"3858","DOI":"10.1182\/blood-2014-04-516211","article-title":"How we treat invasive fungal diseases in patients with acute leukemia: the importance of an individualized approach","volume":"124","author":"Nucci","year":"2014","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.leukres.2023.107341_bib17","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1002\/ajh.23404","article-title":"Acute myeloid leukemia: 2013 update on risk-stratification and management","volume":"88","author":"Estey","year":"2013","journal-title":"Am. J. Hematol."},{"issue":"7","key":"10.1016\/j.leukres.2023.107341_bib18","first-page":"681","article-title":"Risk factors for invasive aspergillosis in acute myeloid leukemia patients prophylactically treated with posaconazole","volume":"49","author":"Michallet","year":"2011","journal-title":"Med. Mycol."},{"issue":"33","key":"10.1016\/j.leukres.2023.107341_bib19","doi-asserted-by":"crossref","first-page":"4417","DOI":"10.1200\/JCO.2011.35.7525","article-title":"Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment assignment","volume":"29","author":"Walter","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.leukres.2023.107341_bib20","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1002\/ajh.26630","article-title":"A dynamic 3-factor survival model for acute myeloid leukemia that accounts for response to induction chemotherapy","volume":"97","author":"Tefferi","year":"2022","journal-title":"Am. J. Hematol."},{"issue":"1","key":"10.1016\/j.leukres.2023.107341_bib21","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1002\/ajh.2830270109","article-title":"Acute myeloblastic leukemia with hyperleukocytosis: risk factors for early mortality in induction","volume":"27","author":"Ventura","year":"1988","journal-title":"Am. J. Hematol."},{"issue":"1","key":"10.1016\/j.leukres.2023.107341_bib22","doi-asserted-by":"crossref","first-page":"46","DOI":"10.3324\/haematol.2013.091819","volume":"99","author":"Bertoli","year":"2014","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.leukres.2023.107341_bib23","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1182\/blood-2006-05-021162","article-title":"Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia","volume":"109","author":"Kantarjian","year":"2007","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.leukres.2023.107341_bib24","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1038\/sj.leu.2404440","article-title":"Intestinal mucosal dysfunction and infection during remission-induction therapy for acute myeloid leukaemia","volume":"20","author":"Bow","year":"2006","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.leukres.2023.107341_bib25","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1200\/JCO.1997.15.6.2254","article-title":"Cytotoxic therapy-induced D-xylose malabsorption and invasive infection during remission-induction therapy for acute myeloid leukemia in adults","volume":"15","author":"Bow","year":"1997","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.leukres.2023.107341_bib26","doi-asserted-by":"crossref","first-page":"284","DOI":"10.3324\/haematol.2014.113399","article-title":"Pre-chemotherapy risk factors for invasive fungal diseases: prospective analysis of 1,192 patients with newly diagnosed acute myeloid leukemia (SEIFEM 2010-a multicenter study)","volume":"100","author":"Caira","year":"2015","journal-title":"Haematologica"},{"issue":"21","key":"10.1016\/j.leukres.2023.107341_bib27","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V118.21.3595.3595","article-title":"Cigarette smoking significantly increases the risk of invasive fungal disease (IFD) in acute myeloid leukemia (AML) patients undergoing induction chemotherapy","volume":"118","author":"Mukherjee","year":"2011","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.leukres.2023.107341_bib28","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1093\/cid\/ciu947","article-title":"Risk factors for invasive fusariosis in patients with acute myeloid leukemia and in hematopoietic cell transplant recipients","volume":"60","author":"Garnica","year":"2015","journal-title":"Clin. Infect. Dis."},{"issue":"8","key":"10.1016\/j.leukres.2023.107341_bib29","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1086\/428780","article-title":"Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases","volume":"191","author":"Kontoyiannis","year":"2005","journal-title":"J. Infect. Dis."},{"issue":"8","key":"10.1016\/j.leukres.2023.107341_bib30","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1086\/591969","article-title":"Epidemiology of invasive mold infections in allogeneic stem cell transplant recipients: biological risk factors for infection according to time after transplantation","volume":"47","author":"Garcia-Vidal","year":"2008","journal-title":"Clin. Infect. Dis."},{"issue":"8","key":"10.1016\/j.leukres.2023.107341_bib31","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1002\/cncr.21792","article-title":"H. Saba, Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study","volume":"106","author":"Kantarjian","year":"2006","journal-title":"Cancer"},{"issue":"10","key":"10.1016\/j.leukres.2023.107341_bib32","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1200\/JCO.2002.04.117","article-title":"Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B","volume":"20","author":"Silverman","year":"2002","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.leukres.2023.107341_bib33","doi-asserted-by":"crossref","first-page":"2814","DOI":"10.1002\/cam4.1231","article-title":"Patterns of infectious complications in acute myeloid leukemia and myelodysplastic syndromes patients treated with 10-day decitabine regimen","volume":"6","author":"Ali","year":"2017","journal-title":"Cancer Med."},{"key":"10.1016\/j.leukres.2023.107341_bib34","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.leukres.2016.01.014","article-title":"Infections in patients with acute myeloid leukemia treated with low-intensity therapeutic regimens: risk factors and efficacy of antibiotic prophylaxis","volume":"42","author":"Bainschab","year":"2016","journal-title":"Leuk. Res."},{"issue":"1","key":"10.1016\/j.leukres.2023.107341_bib35","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.clml.2013.09.014","article-title":"Patterns of infection in patients with myelodysplastic syndromes and acute myeloid leukemia receiving azacitidine as salvage therapy. Implications for primary antifungal prophylaxis","volume":"14","author":"Falantes","year":"2014","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"11","key":"10.1016\/j.leukres.2023.107341_bib36","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1007\/s00277-017-3091-x","article-title":"The impact of antimicrobial prophylaxis in morbidity and infections during azacitidine treatment","volume":"96","author":"Lorenzana","year":"2017","journal-title":"Ann. Hematol."},{"issue":"2","key":"10.1016\/j.leukres.2023.107341_bib37","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1002\/ajh.23368","article-title":"Predicting infections in high-risk patients with myelodysplastic syndrome\/acute myeloid leukemia treated with azacitidine: a retrospective multicenter study","volume":"88","author":"Merkel","year":"2013","journal-title":"Am. J. Hematol."},{"issue":"6","key":"10.1016\/j.leukres.2023.107341_bib38","doi-asserted-by":"crossref","first-page":"e95","DOI":"10.1016\/j.clml.2015.02.030","article-title":"Higher infection rate after 7- compared with 5-day cycle of azacitidine in patients with higher-risk myelodysplastic syndrome","volume":"15","author":"Ofran","year":"2015","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"10","key":"10.1016\/j.leukres.2023.107341_bib39","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1080\/10428194.2017.1295141","article-title":"Incidence, etiology and timing of infections following azacitidine therapy for myelodysplastic syndromes","volume":"58","author":"Trubiano","year":"2017","journal-title":"Leuk. Lymphoma"},{"issue":"7","key":"10.1016\/j.leukres.2023.107341_bib40","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1002\/ajh.25808","article-title":"Risk of invasive fungal infections in patients with high-risk MDS and AML receiving hypomethylating agents","volume":"95","author":"Kim","year":"2020","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.leukres.2023.107341_bib41","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2022.1012334","article-title":"High rate of invasive fungal infections during early cycles of azacitidine for patients with acute myeloid leukemia","volume":"12","author":"Wang","year":"2022","journal-title":"Front. Cell Infect. Microbiol."},{"issue":"8","key":"10.1016\/j.leukres.2023.107341_bib42","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1111\/myc.12500","article-title":"Invasive fungal infections in AML\/MDS patients treated with azacitidine: a risk worth considering antifungal prophylaxis?","volume":"59","author":"Pomares","year":"2016","journal-title":"Mycoses"},{"issue":"24","key":"10.1016\/j.leukres.2023.107341_bib43","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1182\/blood.2020004856","article-title":"Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial","volume":"135","author":"Wei","year":"2020","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.leukres.2023.107341_bib44","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","article-title":"Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia","volume":"133","author":"DiNardo","year":"2019","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.leukres.2023.107341_bib45","doi-asserted-by":"crossref","first-page":"4043","DOI":"10.1182\/bloodadvances.2019000930","article-title":"Invasive fungal infections in acute myeloid leukemia treated with venetoclax and hypomethylating agents","volume":"3","author":"Aldoss","year":"2019","journal-title":"Blood Adv."},{"issue":"8","key":"10.1016\/j.leukres.2023.107341_bib46","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1080\/10428194.2022.2047964","article-title":"Outcomes of antifungal prophylaxis for newly diagnosed AML patients treated with a hypomethylating agent and venetoclax","volume":"63","author":"Chen","year":"2022","journal-title":"Leuk. Lymphoma"},{"issue":"24","key":"10.1016\/j.leukres.2023.107341_bib47","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13246285","article-title":"Infections of venetoclax-based chemotherapy in acute myeloid leukemia: rationale for proper antimicrobial prophylaxis","volume":"13","author":"Lee","year":"2021","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.leukres.2023.107341_bib48","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/bjh.18051","article-title":"Characterisation of infections in patients with acute myeloid leukaemia receiving venetoclax and a hypomethylating agent","volume":"197","author":"On","year":"2022","journal-title":"Br. J. Haematol."},{"issue":"10","key":"10.1016\/j.leukres.2023.107341_bib49","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofac486","article-title":"Incidence of invasive fungal infections in patients with previously untreated acute myeloid leukemia receiving venetoclax and azacitidine","volume":"9","author":"Zhang","year":"2022","journal-title":"Open Forum Infect. Dis."},{"issue":"2","key":"10.1016\/j.leukres.2023.107341_bib50","first-page":"149","article-title":"Clinical hepatotoxicity associated with antifungal agents","volume":"16","author":"Kyriakidis","year":"2017","journal-title":"Expert Opin. Drug Saf."},{"issue":"8","key":"10.1016\/j.leukres.2023.107341_bib51","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1093\/mmy\/myaa008","article-title":"Reasons for voriconazole prophylaxis discontinuation in allogeneic hematopoietic cell transplant recipients: a real-life paradigm","volume":"58","author":"Chan","year":"2020","journal-title":"Med. Mycol."},{"issue":"Suppl 7","key":"10.1016\/j.leukres.2023.107341_bib52","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/imj.15587","article-title":"Antifungal guidelines steering, consensus guidelines for optimising antifungal drug delivery and monitoring to avoid toxicity and improve outcomes in patients with haematological malignancy and haemopoietic stem cell transplant recipients, 2021","volume":"51","author":"Chau","year":"2021","journal-title":"Intern. Med. J."},{"issue":"2","key":"10.1016\/j.leukres.2023.107341_bib53","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.clinthera.2017.01.003","article-title":"Management of venetoclax-posaconazole interaction in acute myeloid leukemia patients: evaluation of dose adjustments","volume":"39","author":"Agarwal","year":"2017","journal-title":"Clin. Ther."},{"issue":"14","key":"10.1016\/j.leukres.2023.107341_bib54","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1002\/cncr.33508","article-title":"Duration of cytopenias with concomitant venetoclax and azole antifungals in acute myeloid leukemia","volume":"127","author":"Rausch","year":"2021","journal-title":"Cancer"},{"issue":"11","key":"10.1016\/j.leukres.2023.107341_bib55","doi-asserted-by":"crossref","first-page":"E422","DOI":"10.1002\/ajh.26707","article-title":"Use of CYP3Ai and impact on outcomes in patients with acute myeloid leukemia treated with venetoclax plus azacitidine in the VIALE \u2013 a study","volume":"97","author":"Jonas","year":"2022","journal-title":"Am. J. Hematol."},{"issue":"4","key":"10.1016\/j.leukres.2023.107341_bib56","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1002\/hon.2646","article-title":"Optimizing venetoclax dose in combination with low intensive therapies in elderly patients with newly diagnosed acute myeloid leukemia: an exposure-response analysis","volume":"37","author":"Agarwal","year":"2019","journal-title":"Hematol. Oncol."},{"issue":"4","key":"10.1016\/j.leukres.2023.107341_bib57","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1177\/1060028020948174","article-title":"Effect of therapeutic drug monitoring and cytochrome P450 2C19 genotyping on clinical outcomes of voriconazole: a systematic review","volume":"55","author":"Lee","year":"2021","journal-title":"Ann. Pharmcother."},{"issue":"10","key":"10.1016\/j.leukres.2023.107341_bib58","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01245-19","article-title":"Impact of triazole therapeutic drug monitoring availability and timing","volume":"63","author":"McCreary","year":"2019","journal-title":"Antimicrob. Agents Chemother."}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212623006069?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212623006069?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T01:04:04Z","timestamp":1758935044000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212623006069"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":58,"alternative-id":["S0145212623006069"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2023.107341","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Should patients with acute myeloid leukemia treated with venetoclax-based regimens receive antifungal prophylaxis?","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2023.107341","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107341"}}